Oncology

Showing 15 posts of 308 posts found.

markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023
Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023
Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …

First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617

December 15, 2023
Research and Development Cullinan Oncology, Oncology, clinical trial, tumours

Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …

Merck and Moderna initiate phase 3 study of NSCLC treatment

December 13, 2023
Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial

Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023
Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023
Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …

Regeneron shares data for multiple myeloma treatment

December 8, 2023
Medical Communications Cancer, Oncology, Regeneron, clinical trial

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023
Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership

ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023
Research and Development Genentech, Oncology, breast cancer, oncology

Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023
Business Services Kling Bio, Oncology, appointment, chief scientific officer

Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer. Dr Gulià has over 15 years …

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023
Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023
Sales and Marketing AbbVie, Oncology, acquisition

AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023
Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours

Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …

The Gateway to Local Adoption Series

Latest content